Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

Just weeks af­ter Mer­ck’s star check­point in­hibitor Keytru­da se­cured FDA ap­proval for a sub­set of blad­der can­cer pa­tients, Swiss com­peti­tor Roche’s Tecen­triq has failed in a piv­otal blad­der can­cer study.

The 809-pa­tient tri­al — IMvig­or010 — test­ed the PD-L1 drug in pa­tients with mus­cle-in­va­sive urothe­lial can­cer (MI­UC) who had un­der­gone surgery, and were at high risk for re­cur­rence.

The ther­a­py failed to meet the main goal of dis­ease-free sur­vival, Roche said, with­out dis­clos­ing de­tails.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER